Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease

This cross-sectional, longitudinal study of amyloid-β–positive individuals with mild cognitive impairment or Alzheimer disease dementia examines the factors associated with interindividual differences in brain and cognitive resilience to tau positron emission tomography load and to changes in global cognition over time.

[1]  C. Jack,et al.  Association of Apolipoprotein E ɛ4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults , 2019, JAMA network open.

[2]  W. M. van der Flier,et al.  Cognitive reserve and clinical progression in Alzheimer disease , 2019, Neurology.

[3]  M. Ewers,et al.  Left frontal connectivity attenuates the adverse effect of entorhinal tau pathology on memory , 2019, Neurology.

[4]  David T. Jones,et al.  Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework , 2019, JAMA neurology.

[5]  C. Jack,et al.  White matter hyperintensities: relationship to amyloid and tau burden. , 2019, Brain : a journal of neurology.

[6]  W. Jagust,et al.  Biomarkers for tau pathology , 2019, Molecular and Cellular Neuroscience.

[7]  Keith A. Johnson,et al.  Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults , 2019, JAMA neurology.

[8]  C. Jack,et al.  Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report , 2019, Brain : a journal of neurology.

[9]  Stephen Salloway,et al.  A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia , 2019, Brain : a journal of neurology.

[10]  L. Beckett,et al.  White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities , 2019, Alzheimer's & dementia.

[11]  Özgür A. Onur,et al.  Level of education mitigates the impact of tau pathology on neuronal function , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  W. M. van der Flier,et al.  Nature and implications of sex differences in AD pathology , 2018, Nature Reviews Neurology.

[13]  B. Miller,et al.  Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.

[14]  Y. Stern,et al.  Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance , 2018, Alzheimer's & Dementia.

[15]  Rik Ossenkoppele,et al.  Is intracranial volume a suitable proxy for brain reserve? , 2018, Alzheimer's Research & Therapy.

[16]  O. Hansson,et al.  Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study , 2018, Alzheimer's Research & Therapy.

[17]  Sterling C. Johnson,et al.  Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau , 2018, JAMA neurology.

[18]  Philip S. Insel,et al.  Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease , 2019, Neurology.

[19]  Prashanthi Vemuri,et al.  Resistance vs resilience to Alzheimer disease , 2018, Neurology.

[20]  Christopher G Schwarz,et al.  Longitudinal tau PET in ageing and Alzheimer’s disease , 2018, Brain : a journal of neurology.

[21]  W. M. van der Flier,et al.  Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease , 2018, Neurology.

[22]  Daniel R. Schonhaut,et al.  Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease , 2017, Brain : a journal of neurology.

[23]  Rik Ossenkoppele,et al.  Distinct 18F‐AV‐1451 tau PET retention patterns in early‐ and late‐onset Alzheimer's disease , 2017, Brain : a journal of neurology.

[24]  K. Fliessbach,et al.  Tau pathology and cognitive reserve in Alzheimer's disease , 2017, Neurobiology of Aging.

[25]  W. M. van der Flier,et al.  A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease , 2017, Human brain mapping.

[26]  William J. Jagust,et al.  Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease , 2017, NeuroImage.

[27]  C. Jack,et al.  Age and sex specific prevalences of cerebral β-amyloidosis, tauopathy and neurodegeneration among clinically normal individuals aged 50-95 years: a cross-sectional study , 2017, The Lancet Neurology.

[28]  Mark E Bastin,et al.  Sex Differences in the Adult Human Brain: Evidence from 5216 UK Biobank Participants , 2017, bioRxiv.

[29]  Keith A. Johnson,et al.  Cognitive resilience in clinical and preclinical Alzheimer’s disease: the Association of Amyloid and Tau Burden on cognitive performance , 2017, Brain Imaging and Behavior.

[30]  Timothy J. Hohman,et al.  Asymptomatic Alzheimer disease , 2016, Neurology.

[31]  Hanna Cho,et al.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum , 2016, Annals of neurology.

[32]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[33]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[34]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[35]  Sébastien Ourselin,et al.  Bayesian Model Selection for Pathological Neuroimaging Data Applied to White Matter Lesion Segmentation , 2015, IEEE Transactions on Medical Imaging.

[36]  Michel Goedert,et al.  Tau pathology and neurodegeneration , 2013, The Lancet Neurology.

[37]  William Jagust,et al.  Vulnerable Neural Systems and the Borderland of Brain Aging and Neurodegeneration , 2013, Neuron.

[38]  Y. Stern.  Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.

[39]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[40]  Yuan Yuan,et al.  Accelerated aging-related transcriptome changes in the female prefrontal cortex , 2012, Aging cell.

[41]  L. Nyberg,et al.  Memory aging and brain maintenance , 2012, Trends in Cognitive Sciences.

[42]  K. Jellinger,et al.  Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.

[43]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[44]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[45]  Nick C Fox,et al.  Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele , 2011, The Lancet Neurology.

[46]  David A Wolk,et al.  Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer’s disease , 2010, Proceedings of the National Academy of Sciences.

[47]  B. Winblad,et al.  Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials , 2009, Current medical research and opinion.

[48]  J. Durlak.  How to select, calculate, and interpret effect sizes. , 2009, Journal of pediatric psychology.

[49]  C. Pike,et al.  Protective actions of sex steroid hormones in Alzheimer’s disease , 2009, Frontiers in Neuroendocrinology.

[50]  Paul M. Thompson,et al.  Mapping the effect of APOE ε4 on gray matter loss in Alzheimer's disease in vivo , 2009, NeuroImage.

[51]  P. Matthews,et al.  Distinct patterns of brain activity in young carriers of the APOE e4 allele , 2009, NeuroImage.

[52]  Carl W. Cotman,et al.  Gene expression changes in the course of normal brain aging are sexually dimorphic , 2008, Proceedings of the National Academy of Sciences.

[53]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[54]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[55]  R. Woods,et al.  Sex differences in cortical thickness mapped in 176 healthy individuals between 7 and 87 years of age. , 2007, Cerebral cortex.

[56]  Sun I. Kim,et al.  Gender difference analysis of cortical thickness in healthy young adults with surface-based methods , 2006, NeuroImage.

[57]  T. Kirkwood,et al.  Understanding the Odd Science of Aging , 2005, Cell.

[58]  K. Rockwood,et al.  Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[59]  G. Alexander,et al.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[60]  M. Todd,et al.  Human Brain Mapping , 2003 .

[61]  K. Hall,et al.  The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. , 1998, Archives of general psychiatry.